These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37036218)

  • 1. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
    Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
    J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
    Front Immunol; 2022; 13():836338. PubMed ID: 35300335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study.
    Hong ZN; Weng K; Peng K; Chen Z; Lin J; Kang M
    Front Oncol; 2021; 11():797426. PubMed ID: 34970498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Wang Y; Ma K; Zhang H; Wu L; Liu L; Zhou Y; Peng L; Wang Q; Zhuang X
    BMC Cancer; 2024 Oct; 24(1):1228. PubMed ID: 39369225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching.
    Hong ZN; Zhang Z; Chen Z; Weng K; Peng K; Lin J; Kang M
    Esophagus; 2022 Apr; 19(2):224-232. PubMed ID: 34988773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
    Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
    Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
    Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
    Zhao J; Hao S; Tian J; Li Y; Han D
    J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.
    Duan X; Zhao F; Shang X; Yue J; Chen C; Ma Z; Chen Z; Zhang C; Pang Q; Zhang W; Abbas AE; Jiang H
    Cancer Med; 2024 Aug; 13(15):e70113. PubMed ID: 39136674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.
    Zhao Y; Xia M; Dang Y; Li Y; Zhao X; Kang N; Zuo J; Zhang R
    Ann Ital Chir; 2024; 95(3):284-293. PubMed ID: 38918965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma].
    Chen R; Fu JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):312-318. PubMed ID: 37072306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials.
    Shen D; Chen R; Wu Q; Ji Y; van der Wilk BJ; Chen EY; Chen Q; Chen M
    J Gastrointest Oncol; 2024 Jun; 15(3):841-850. PubMed ID: 38989436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
    Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
    Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma.
    Ma S; Yan T; Liu D; Wang K; Wang J; Song J; Wang T; He W; Bai J; Jin L; Chen X
    Thorac Cancer; 2018 Feb; 9(2):310-315. PubMed ID: 29319236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.
    Xie SH; Yang LT; Zhang H; Tang ZL; Lin ZW; Chen Y; Hong ZN; Xu RY; Lin WL; Kang MQ
    Front Immunol; 2024; 15():1332492. PubMed ID: 38375480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.